Eagle Pharmaceuticals (EGRX) PT Raised to $50 at Cantor Fitzgerald, Following Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts EGRX Hot Sheet
Price: $2.14 --0%
Rating Summary:
2 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
2 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
Cantor Fitzgerald analyst Brandon Folkes raised the price target on Eagle Pharmaceuticals (NASDAQ: EGRX) to $50.00 (from $46.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Essential Properties Realty Trust (EPRT) PT Lowered to $31 at Cantor Fitzgerald
- Vertex (VRTX) PT Raised to $619 at Cantor Fitzgerald
- Ideaya Biosciences (IDYA) PT Lowered to $57 at Truist Securities
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Cantor Fitzgerald, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
